Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis

Annual Review of Clinical Psychology

Volumn 10, Issue , 2014, Pages 767-791

  Van Winkel, Ruud ^a,b   Kuepper, Rebecca ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cannabidiol; Gene environment interaction; Psychosis; Schizophrenia; THC

Indexed keywords

ACETYLCHOLINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CATECHOL METHYLTRANSFERASE; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; PSYCHEDELIC AGENT; SEROTONIN; VANILLOID RECEPTOR;

ANTERIOR CINGULATE; BASAL GANGLION; BRAIN FUNCTION; CANNABIS USE; CEREBELLUM; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL STRESS; FUNCTIONAL NEUROIMAGING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HIGH RISK BEHAVIOR; HIPPOCAMPUS; HUMAN; INTOXICATION; LEARNING; MEMORY DISORDER; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OCCIPITAL CORTEX; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; PURKINJE CELL; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SELF MEDICATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA PARS RETICULATA; SUPERIOR TEMPORAL GYRUS; SYSTEMATIC REVIEW (TOPIC); URBAN AREA;

AGE OF ONSET; BRAIN; CAUSALITY; ENDOCANNABINOIDS; GENE-ENVIRONMENT INTERACTION; HUMANS; MARIJUANA SMOKING; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 84897446932     PISSN: 15485943     EISSN: 15485951     Source Type: Book Series    
DOI: 10.1146/annurev-clinpsy-032813-153631     Document Type: Review

References (143)

1. Alemany S, Arias B, Fatjo-Vilas M, Villa H, Moya J, et al. 2014. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr. Scand. 129:54-62
2. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, et al. 2012. Modulation of L-Alphalysophosphatidylinositol/GPR55 mitogen-Activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287:91-104
3. Arnold JC, Boucher AA, Karl T. 2012. The yin and yang of cannabis-induced psychosis: The actions of -(9)-Tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr. Pharm. Des. 18:5113-30
4. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. 2008. Corpus callosum damage in heavy marijuana use: Preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. NeuroImage 41:1067-74
5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. 2002. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325:1212-13
6. Azad SC, Kurz J, Marsicano G, Lutz B, Zieglgansberger W, Rammes G. 2008. Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learn. Mem. 15:143-52
7. Bacci A, Huguenard JR, Prince DA. 2004. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 431:312-16
8. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, et al. 2011. Does intravenous-9-Tetrahydrocannabinol increase dopamine release? A SPET study. J. Psychopharmacol. 25:1462-68
9. Batalla A, Soriano-Mas C, Lopez-Sola M, Torrens M, Crippa JA, et al. 2013. Modulation of brain structure by catechol-o-methyltransferase Val(158)Met polymorphism in chronic cannabis users. Addict. Biol. In press. doi:10.1111/adb.12027
10. Battisti RA, Roodenrys S, Johnstone SJ, Pesa N, Hermens DF, Solowij N. 2010. Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution. Psychopharmacology 212:613-24
11. Behan A, Hryniewiecka M, O'Tuathaigh CM, Kinsella A, Cannon M, et al. 2012. Chronic adolescent exposure to delta-9-Tetrahydrocannabinol in COMT mutant mice: Impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 37:1773-83
12. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, et al. 2012. Induction of psychosis by-9-Tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 69:27-36
13. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, et al. 2010. Opposite effects of -9-Tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764-74
14. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD. 2013. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry. In press
15. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, et al. 2008. Neural basis of -9-Tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biol. Psychiatry 64:966-73
16. Bossong MG, Niesink RJ. 2010. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 92:370-85
17. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, et al. 2009. Delta 9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34:759-66
18. Broyd SJ, Greenwood LM, Croft RJ, Dalecki A, Todd J, et al. 2013. Chronic effects of cannabis on sensory gating. Int. J. Psychophysiol. 89:381-89
19. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, et al. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57:1117-27
20. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. 2012. Endocannabinoid signaling and synaptic function. Neuron 76:70-81
21. Chavez AE, Chiu CQ, Castillo PE. 2010. TRPV1 activation by endogenous anandamide triggers postsynaptic long-Term depression in dentate gyrus. Nat. Neurosci. 13:1511-18
22. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75:807-21
23. Chevaleyre V, Takahashi KA, Castillo PE. 2006. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29:37-76
24. Costas J, Sanjuan J, Ramos-Rios R, Paz E, Agra S, et al. 2011. Interaction between COMT haplotypes and cannabis in schizophrenia: A case-only study in two samples from Spain. Schizophr. Res. 127:22-27
25. Cougnard A, Marcelis M, Myin-Germeys I, De Graaf R, Vollebergh W, et al. 2007. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol. Med. 37:513-27
26. Cross-Disord. Group Psychiatr. Genomics Consort., Smoller JW, Craddock N, Kendler KS, Lee PH, et al. 2013. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381:1371-79
27. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, et al. 2004. The psychotomimetic effects of intravenous delta-9-Tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29:1558-72
28. Decoster J, Van Os J, Myin-Germeys I, De Hert M, van Winkel R. 2012. Genetic variation underlying psychosis-inducing effects of cannabis: Critical review and future directions. Curr. Pharm. Des. 18:5015-23
29. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, et al. 2011. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. Drug Alcohol Depend. 114:242-45
30. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-49
31. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone A, et al. 2012. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol. Psychiatry 72:811-16
32. Dominguez MD, Wichers M, Lieb R, Wittchen HU, van Os J. 2011. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: An 8-year cohort study. Schizophr. Bull. 37:84-93
33. Duncan LE, Keller MC. 2011. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am. J. Psychiatry 168:1041-49
34. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, et al. 2013. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol. Psychiatry 74:106-12
35. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, et al. 1999. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142:295-301
36. El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET. 2012. Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 38:36-50
37. Englund A, Morrison PD, Nottage J, Hague D, Kane F, et al. 2013. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 27:19-27
38. Estrada G, Fatj́o-Vilas M, Muñoz MJ, Pulido G, Miñano MJ, et al. 2011. Cannabis use and age at onset of psychosis: Further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr. Scand. 123:485-92
39. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. 2005. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100:612-18
40. Fergusson DM, Horwood LJ, Swain-Campbell NR. 2003. Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 33:15-21
41. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, et al. 2010. Modulation of effective connectivity during emotional processing by -9-Tetrahydrocannabinol and cannabidiol. Int. J. Neuropsychopharmacol. 13:421-32
42. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, et al. 2009. Distinct effects of -9-Tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 66:95-105
43. Genetic Risk Outcome Psychos. (GROUP) Investig. 2011. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: An analysis of patient-sibling and sibling-control pairs. Arch. Gen. Psychiatry 68:138-47
44. Grueter BA, Brasnjo G, Malenka RC. 2010. Postsynaptic TRPV1 triggers cell type-specific long-Term depression in the nucleus accumbens. Nat. Neurosci. 13:1519-25
45. Gutíerrez B, Rivera M, Obel L, McKenney K, Mart́inez-Leal R, et al. 2009. Variability in the COMT gene and modification of the risk of schizophrenia conferred by cannabis consumption. Rev. Psiquiatr. Salud Ment. 2:89-94
46. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J. 2011. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiatry 69:487-94
47. Hall W, Solowij N. 1998. Adverse effects of cannabis. Lancet 352:1611-16
48. Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, et al. 2010. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol. Med. 40:1627-34
49. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, et al. 2005a. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330:11-14
50. Henquet C, Murray R, Linszen D, van Os J. 2005b. The environment and schizophrenia: The role of cannabis use. Schizophr. Bull. 31:608-12
51. Henquet C, Rosa A, Delespaul P, Papiol S, Fananas L, et al. 2009. COMT ValMet moderation of cannabisinduced psychosis: A momentary assessment study of "switching on" hallucinations in the flow of daily life. Acta Psychiatr. Scand. 119:156-60
52. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, et al. 2006. An experimental study of catechol-omethyltransferase Val158Met moderation of delta-9-Tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31:2748-57
53. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR. 2007. Opposing actions of chronic -9-Tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-Term potentiation. Learn. Mem. 14:63-74
54. Hollis C, Groom MJ, Das D, Calton T, Bates AT, et al. 2008. Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder (ADHD). Schizophr. Res. 105:216-23
55. Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. 2008. Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey. Schizophr. Bull. 34:580-85
56. Houston JE, Murphy J, Shevlin M, Adamson G. 2011. Cannabis use and psychosis: Re-visiting the role of childhood trauma. Psychol. Med. 41:2339-48
57. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, et al. 2012. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 69:776-86
58. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG. 2011. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br. J. Pharmacol. 163:1329-43
59. Kantrowitz JT, Nolan KA, Sen S, Simen A, Lachman HM, Bowers M. 2009. Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. Psychiatr.Q. 80:213-18
60. Klugmann M, Klippenstein V, Leweke FM, Spanage lR, Schneider M. 2011. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. Int. J. Neuropsychopharmacol. 14:505-17
61. Konings M, Bak M, Hanssen M, van Os J, Krabbendam L. 2006. Validity and reliability of the CAPE: A selfreport instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr. Scand. 114:55-61
62. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J. 2008. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr. Scand. 118:209-13
63. Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, et al. 2012. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med. 42:149-59
64. Kuepper R, Ceccarini J, Lataster J, Van Os J, Van Kroonenburgh M, et al. 2013. Delta-9-Tetrahydrocannabinol-induced dopamine release as a function of psychosis risk:18F-fallypride positron emission tomography study. PLoS ONE 8:e70378
65. Kuepper R, Henquet C, Lieb R, Wittchen HU, van Os J. 2011a. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr. Res. 131:262-63
66. Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C. 2010. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 121:107-17
67. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C. 2011b. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol. Med. 41:2121-9
68. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. 2011c. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 342:d738
69. Littleton JM, MacLean KI, Brownlee G. 1976. Proceedings: Alterations in dopamine uptake in rat corpus striatum induced by combinations of stress and delta8-Tetrahydrocannabinol (delta8-THC). Br. J. Pharmacol. 56:370P
70. Lopez-Moreno JA, Gonzalez-Cuevas G, Moreno G, Navarro M. 2008. The pharmacology of the endocannabinoid system: Functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict. Biol. 13:160-87
71. Lundqvist T. 2005. Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav. 81:319-30
72. Mackie K. 2005. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168:299-325
73. MacLean KI, Littleton JM. 1977. Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-Tetrahydrocannabinol. Eur. J. Pharmacol. 41:171-82
74. Marinelli S, Pacioni S, Cannich A, Marsicano G, Bacci A. 2009. Self-modulation of neocortical pyramidal neurons by endocannabinoids. Nat. Neurosci. 12:1488-90
75. Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, et al. 2010. Neuroimaging in cannabis use: A systematic review of the literature. Psychol. Med. 40:383-98
76. Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, Manzoni OJ. 2004. A single in-vivo exposure to delta 9 THC blocks endocannabinoid-mediated synaptic plasticity. Nat. Neurosci. 7:585-86
77. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, et al. 2010. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 67:440-47
78. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90
79. Mechoulam R, Parker LA, Gallily R. 2002. Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. 42:11-19S
80. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, et al. 2012. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. USA 109:E2657-64
81. Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, et al. 2013. Dopamine response to psychosocial stress in chronic cannabis users: A PET study with [(11)C]-(+)-PHNO. Neuropsychopharmacology 38:673-82
82. Mokler DJ, Robinson SE, Johnson JH, Hong JS, Rosecrans JA. 1987. Neonatal administration of delta-9-Tetrahydrocannabinol (THC) alters the neurochemical response to stress in the adult Fischer-344 rat. Neurotoxicol. Teratol. 9:321-27
83. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370:319-28
84. Morgan CJ, Curran HV. 2008. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 192:306-7
85. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, et al. 2012. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol. Med. 42:391-400
86. Morgan CJ, Schafer G, Freeman TP, Curran HV. 2010. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study [corrected]. Br. J. Psychiatry 197:285-90
87. Morrison PD, Murray RM. 2009. From real-world events to psychosis: The emerging neuropharmacology of delusions. Schizophr. Bull. 35:668-74
88. Morrison PD, Stone JM. 2011. Synthetic delta-9-Tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum. Psychopharmacol. 26:77-80
89. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, et al. 2009. The acute effects of synthetic intravenous Delta9-Tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 39:1607-16
90. Murphy J, Houston JE, Shevlin M, Adamson G. 2013. Childhood sexual trauma, cannabis use and psychosis: Statistically controlling for pre-Trauma psychosis and psychopathology. Soc. Psychiatry Psychiatr. Epidemiol. 48:853-61
91. Murray RM, Morrison PD, Henquet C, Di Forti M. 2007. Cannabis, the mind and society: The hash realities. Nat. Rev. 8:885-95
92. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. 2012. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18:119-32
93. O'Tuathaigh CM, Clarke G, Walsh JJ, Desbonnet L, Petit E, et al. 2012. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol. 15:1331-42
94. O'Tuathaigh CM, Hryniewiecka M, Behan A, Tighe O, Coughlan C, et al. 2010. Chronic adolescent exposure to delta-9-Tetrahydrocannabinol in COMT mutant mice: Impact on psychosis-related and other phenotypes. Neuropsychopharmacology 35:2262-73
95. Pelayo-Teran JM, Perez-Iglesias R, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B. 2010. Catechol-O-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-Affective psychosis: Clinical-onset implications. Psychiatr. Res. 179:291-96
96. Pertwee RG. 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:129-80
97. Pertwee RG. 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-Tetrahydrocannabinol, cannabidiol and delta9-Tetrahydrocannabivarin. Br. J. Pharmacol. 153:199-215
98. Pertwee RG. 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17:1360-81
99. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. 2004. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol. Psychiatry 56:86-94
100. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D 2003. Early-onset cannabis use and cognitive deficits: What is the nature of the association? Drug Alcohol Depend. 69:303-10
101. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-52
102. Rabin RA, Zakzanis KK, George TP. 2011. The effects of cannabis use on neurocognition in schizophrenia: A meta-Analysis. Schizophr. Res. 128:111-16
103. Ranganathan M, D'Souza DC. 2006. The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology 188:425-44
104. Realini N, Rubino T, Parolaro D. 2009. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol. Res. 60:132-38
105. Rubino T, Realini N, Braida D, Guidi S, Capurro V, et al. 2009. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19:763-72
106. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, et al. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152:1092-101
107. Schneider M, Drews E, Koch M. 2005. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonistWIN 55,212-2. Behav. Pharmacol. 16:447-54
108. Schneider M, Koch M. 2003. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760-69
109. Schneider M, Koch M. 2007. The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur. Neuropsychopharmacol. 17:180-86
110. Schneider M, Schomig E, Leweke FM. 2008. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 13:345-57
111. Schubart CD, Boks MP, Breetvelt EJ, van Gastel WA, Groenwold RH, et al. 2011a. Association between cannabis and psychiatric hospitalization. Acta Psychiatr. Scand. 123:368-75
112. Schubart CD, Sommer IE, van Gaste lWA, Goetgebuer RL, Kahn RS, Boks MP. 2011b. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr. Res. 130:216-21
113. Smith MJ, Barch DM, Wolf T, Mamah D, Csernansky JG. 2008. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr. Res. 106:294-99
114. Solowij N 1995. Do cognitive impairments recover following cessation of cannabis use? Life Sci. 56:2119-26
115. Solowij N, Battisti R. 2008. The chronic effects of cannabis on memory in humans: A review. Curr. Drug Abuse Rev. 1:81-98
116. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, et al. 2002. Cognitive functioning of long-Term heavy cannabis users seeking treatment. JAMA 287:1123-31
117. Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, et al. 2013. Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr. Res. 143:179-84
118. Solowij N, Yücel M, Respondek C, Whittle S, Lindsay E, et al. 2011. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol. Med. 41:2349-59
119. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. 2004. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99:1333-41
120. Stokes PR, Egerton A, Watson B, Reid A, Breen G, et al. 2010. Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. NeuroImage 52:1521-27
121. Stokes PR, Egerton A, Watson B, Reid A, Lappin J, et al. 2012. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J. Psychopharmacol. 26:144-49
122. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM 2009. Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 48:186-90
123. Stowkowy J, Addington J. 2013. Predictors of a clinical high risk status among individuals with a family history of psychosis. Schizophr. Res. 147:281-86
124. Sullivan PF. 2007. Spurious genetic associations. Biol. Psychiatry 61:1121-26
125. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, et al. 2012. Dopamine release in chronic cannabis users: A [11c]raclopride positron emission tomography study. Biol. Psychiatry 71:677-83
126. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. 2009. A systematic review and metaanalysis of the psychosis continuum: Evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol. Med. 39:179-95
127. van Os J, Rutten BP, Poulton R. 2008. Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr. Bull. 34:1066-82
128. vanWinkel R, Esquivel G, Kenis G, Wichers M, Collip D, et al. 2010. Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neurosci. Ther. 16:e185-92
129. van Winkel R, Genetic Risk Outcome Psychos. (GROUP) Investig. 2011. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Arch. Gen. Psychiatry 68:148-57
130. vanWinkel R, Genetic Risk Outcome Psychos. (GROUP) Investig. 2013. Family-based study examiningmoderation of familial correlation in psychosis-related experiences by the environment. Manuscr. submitted
131. vanWinkel R, van Beveren JM, Genetic Risk Outcome Psychos. (GROUP) Investig. 2011. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 36:2529-37
132. Veling W, Mackenbach JP, van Os J, HoekHW.2008. Cannabis use and genetic predisposition for schizophrenia: A case-control study. Psychol. Med. 38:1251-56
133. Verdejo-Garcia A, Beatriz Fagundo A, Cuenca A, Rodriguez J, Cuyas E, et al. 2013. COMT Val158Met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology 38:1598-606
134. Vinkers C, Van Gastel WA, Schubart CD, Van Eijk K, Luykx J, et al. 2013. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by theCOMTVal158Met polymorphism. Schizophr. Res. 150:303-11
135. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. 2001. Cannabis induced dopamine release: An in-vivo SPECT study. Psychiatry Res. 107:173-77
136. Wegener N, Koch M. 2009. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res. 1253:81-91
137. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. 2000. Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study. J. Addict. Dis. 19:1-22
138. Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, et al. 2011. Modulation of auditory and visual processing by delta-9- Tetrahydrocannabinol and cannabidiol: An FMRI study. Neuropsychopharmacology 36:1340-48
139. Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, et al. 2012. The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-Analysis of existing findings and new data in a firstepisode sample. Schizophr. Bull. 38:316-30
140. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, et al. 2008. Regional brain abnormalities associated with long-Term heavy cannabis use. Arch. Gen. Psychiatry 65:694-701
141. Zammit S, Owen M, Evans J, Heron J, Lewis G. 2011. Cannabis, COMT and psychotic experiences. Br. J. Psychiatry 199:380-85
142. Zammit S, Spurlock G, Williams H, Norton N, Williams N, et al. 2007. Genotype effects of CHRNA7,CNR1 and COMT in schizophrenia: Interactions with tobacco and cannabis use. Br. J. Psychiatry 191:402-7
143. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, et al. 2012. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 18:5131-40.